Citigroup Reiterates Buy on Silk Road Medical, Maintains $48 Price Target
Portfolio Pulse from richadhand@benzinga.com
Citigroup analyst Joanne Wuensch has reiterated a 'Buy' rating on Silk Road Medical (NASDAQ:SILK) and maintained a price target of $48.
July 11, 2023 | 2:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup has reiterated a 'Buy' rating on Silk Road Medical and maintained a price target of $48.
The 'Buy' rating from Citigroup, a major financial institution, is a positive signal for Silk Road Medical. The maintained price target of $48 indicates that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100